Skip to Main Content

INFORMATION FOR

    Xiaojia (Sasha) Guo, PhD

    Research Scientist (Nephrology)
    DownloadHi-Res Photo

    About

    Titles

    Research Scientist (Nephrology)

    Appointments

    Other Departments & Organizations

    Education & Training

    Postdoctoral fellow
    Weill Medical College of Cornell Univ (2000)
    PhD
    Rutgers University, Cell and Developmental Biology (1994)
    MSc
    University of Western Ontario, Biochemistry (1990)
    BA
    Jiangxi University, Microbilogy (1982)

    Research

    Overview

    We have shown that ESDN down-regulation by RNA interference significantly enhanced PDGF-induced VSMC DNA synthesis and migration. This was associated with increased ERK1/2, Src, and PDGF receptor (PDGFR) phosphorylation, without altering total PDGFR expression levels. In binding assays, ESDN down-regulation significantly increased 125I-PDGF maximum binding (Bmax) to PDGF receptors on VSMCs without altering the binding constant (Kd), raising the possibility that ESDN regulates PDGFR processing. ESDN down-regulation significantly reduced ligand-induced PDGFR ubiquitination. This was associated with a significant reduction in the expression level of c-Cbl, an E3 ubiquitin ligase that ubiquitinylates PDGFR. Thus, ESDN modulates PDGF signaling in VSMCs via regulation ofPDGFRsurface levels. The ESDN effect is mediated, at least in part, through effects on PDGFR ubiquitination.

    Continued detailed analyses of the involvement of ESDN in the regulation of RTK-driven pathologies is thus predicted to pave the way for therapeutic strategy for vascular diseases and other diseases involving RTK-driven tissue remodeling.

    Medical Research Interests

    Nephrology; Vascular Remodeling

    Research at a Glance

    Yale Co-Authors

    Frequent collaborators of Xiaojia (Sasha) Guo's published research.

    Publications

    2024

    2023

    2022

    Academic Achievements & Community Involvement

    • activity

      West Haven VA Medical Center

    • activity

      Utility of Renalase as a Novel Biomarker to Stratify Pancreatic Adenocarcinoma Candidates for Surgery

    • activity

      Heightened Innate Immune Response to COVID-19 Infection in CKD: Implications to Poorer Outcome During CKD.

    • activity

      mRNA editing via Apobec-1 limits regulated necrosis from cisplatin (CP)-induced Acute Kidney Injury (AKI) by regulating the disposal of pro-ferroptotic triglycerides

    • activity

      A Renalase Peptide Encapsulated in Renal-selective Mesoscale Nanoparticle Protected Cisplatin-induced Chronic Kidney Disease

    Get In Touch

    Contacts

    Locations